Franzen N - Search Results

1

Impact of organ-on-a-chip technology on pharmaceutical R&D costs.

Franzen N, van Harten WH, Retèl VP, Loskill P, van den Eijnden-van Raaij J, IJzerman M. Franzen N, et al. Drug Discov Today. 2019 Sep;24(9):1720-1724. doi: 10.1016/j.drudis.2019.06.003. Epub 2019 Jun 8. Drug Discov Today. 2019. PMID: 31185290 Free article. Review.

2

Evidence Underlying Policy Proposals for Sustainable Anticancer Drug Prices: A Systematic Review.

Franzen N, Retèl VP, Schats W, van Harten WH. Franzen N, et al. JAMA Oncol. 2020 Jun 1;6(6):909-916. doi: 10.1001/jamaoncol.2019.6846. JAMA Oncol. 2020. PMID: 32215592

3

Improving the Affordability of Anticancer Medicines Demands Evidence-Based Policy Solutions.

Franzen N, Romagnoli G, Ziegler A, Retèl VP, Offerman TJS, van Harten WH. Franzen N, et al. Cancer Discov. 2022 Feb;12(2):299-302. doi: 10.1158/2159-8290.CD-21-1153. Epub 2022 Jan 27. Cancer Discov. 2022. PMID: 35086923

4

Securing sustainable price levels of innovative anticancer drugs: How to move forward?

Franzen N, Retèl V, van Harten W. Franzen N, et al. J Cancer Policy. 2021 Mar;27:100266. doi: 10.1016/j.jcpo.2020.100266. Epub 2020 Dec 26. J Cancer Policy. 2021. PMID: 35559942

5

Affordable Prices Without Threatening the Oncological R&D Pipeline-An Economic Experiment on Transparency in Price Negotiations.

Franzen N, Ziegler A, Romagnoli G, Retèl VP, Offerman TJS, van Harten WH. Franzen N, et al. Cancer Res Commun. 2022 Jan 27;2(1):49-57. doi: 10.1158/2767-9764.CRC-21-0031. eCollection 2022 Jan. Cancer Res Commun. 2022. PMID: 36860697 Free PMC article. Clinical Trial.

6

Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe.

Vancoppenolle JM, Koole SN, O'Mahony JF, Franzen N, Burgers JA, Retèl VP, van Harten WH. Vancoppenolle JM, et al. Among authors: franzen n. Drug Discov Today. 2023 Aug;28(8):103620. doi: 10.1016/j.drudis.2023.103620. Epub 2023 May 16. Drug Discov Today. 2023. PMID: 37201780 Free article.

7

Differences in time to patient access to innovative cancer medicines in six European countries.

Vancoppenolle JM, Franzen N, Koole SN, Retèl VP, van Harten WH. Vancoppenolle JM, et al. Among authors: franzen n. Int J Cancer. 2024 Mar 1;154(5):886-894. doi: 10.1002/ijc.34753. Epub 2023 Oct 20. Int J Cancer. 2024. PMID: 37864395

8

The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research directions.

Schlander M, van Harten W, Retèl VP, Pham PD, Vancoppenolle JM, Ubels J, López OS, Quirland C, Maza F, Aas E, Crusius B, Escobedo A, Franzen N, Fuentes-Cid J, Hernandez D, Hernandez-Villafuerte K, Kirac I, Paty A, Philip T, Smeland S, Sullivan R, Vanni E, Varga S, Vermeulin T, Eckford RD. Schlander M, et al. Among authors: franzen n. Lancet Oncol. 2024 Apr;25(4):e152-e163. doi: 10.1016/S1470-2045(23)00636-8. Lancet Oncol. 2024. PMID: 38547899 Review.

9

Executive functions in borderline personality disorder.

Hagenhoff M, Franzen N, Koppe G, Baer N, Scheibel N, Sammer G, Gallhofer B, Lis S. Hagenhoff M, et al. Among authors: franzen n. Psychiatry Res. 2013 Nov 30;210(1):224-31. doi: 10.1016/j.psychres.2013.05.016. Epub 2013 Jun 10. Psychiatry Res. 2013. PMID: 23764434

10

Social Interaction Behavior in ADHD in Adults in a Virtual Trust Game.

Lis S, Baer N, Franzen N, Hagenhoff M, Gerlach M, Koppe G, Sammer G, Gallhofer B, Kirsch P. Lis S, et al. Among authors: franzen n. J Atten Disord. 2016 Apr;20(4):335-45. doi: 10.1177/1087054713482581. Epub 2013 Apr 5. J Atten Disord. 2016. PMID: 23564736

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18 results

Search Page